$5.4m · Other round · Healthtech · London, UK
London-based Mirae has announced $5.4m in funding led by Oxford Science Enterprises to develop an AI-supported continuous-care platform for autoimmune disease and other complex chronic conditions. The company is starting with inflammatory bowel disease (IBD), where symptoms, medication responses and flares can change between appointments.
Mirae's announcement says the platform is being deployed with a leading US health system, although it does not name the organisation. The funding round's other participants and formal stage were not disclosed; EUVC therefore follows Tech.eu's Other classification.
Turning the gaps between visits into usable clinical context
Mirae is designed to capture symptoms, behaviours, medications, laboratory results and treatment changes as they occur, then organise them into a longitudinal record for patients and clinicians. Its patient-facing conversational AI asks follow-up questions and identifies patterns, while its clinician product presents a structured assessment built from the patient's history, reported changes and clinical evidence.
The commercial premise is that specialist care is constrained not only by appointment capacity but by missing context. Clinicians often spend part of a short consultation reconstructing what happened since the previous visit. If Mirae can make that history reviewable before the appointment, it could shift time towards treatment decisions and follow-up. That value, however, depends on the quality of patient input, the reliability of the system's synthesis and clinicians' willingness to use it alongside existing records.
The company says its technology builds on work from the University of Oxford's Computational Health Informatics Lab, led by academic co-founder Professor David Clifton. Founder and CEO Anuj Patel previously founded autoimmune-care company Motto Health, while co-founder and CTO James Nishiyama Finucane was CTO of African health company mPharma.
Adoption starts without an integration project
Mirae's current clinician offer lets individual gastroenterologists, nurse practitioners and physician associates start with a patient before a practice-wide rollout. Patients connect their own records through HealthEx, and Mirae says clinicians do not need an EHR integration to begin. This lowers the initial implementation threshold, but broader institutional adoption will still depend on governance, privacy controls, clinical validation and evidence that the product improves care rather than simply adding another information layer.
The company states clearly that Mirae does not diagnose or prescribe and does not replace clinical judgement. Oxford Science Enterprises argues that the opportunity lies in conditions where patient context and clinical evidence must be combined over time. The new capital gives Mirae room to test whether that continuous-data model can translate from an IBD-focused product into a repeatable care workflow.
